Abstract
ObjectiveTo examine whether treatment with the antiviral agent molnupiravir during the first five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse health outcomes.DesignCohort study.SettingUS Department of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have